111 related articles for article (PubMed ID: 9494598)
21. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk.
Sauter ER; Daly M; Linahan K; Ehya H; Engstrom PF; Bonney G; Ross EA; Yu H; Diamandis E
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):967-70. PubMed ID: 8959318
[TBL] [Abstract][Full Text] [Related]
22. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
Kristiansen G; Pilarsky C; Pervan J; Stürzebecher B; Stephan C; Jung K; Loening S; Rosenthal A; Dietel M
Prostate; 2004 Feb; 58(2):183-92. PubMed ID: 14716744
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
25. Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells.
Bodey B; Bodey B; Kaiser HE
Anticancer Res; 1997; 17(4A):2577-81. PubMed ID: 9252683
[TBL] [Abstract][Full Text] [Related]
26. [Characteristics of prostatic cancer in men with a serum prostate-specific antigen level of < or =4.0 ng/ml].
Ono Y; Chiba K; Tanaka H
Hinyokika Kiyo; 2005 Oct; 51(10):647-50. PubMed ID: 16285616
[TBL] [Abstract][Full Text] [Related]
27. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
29. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
30. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
31. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
32. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
33. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
34. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
35. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
Stimpfl M; Tong D; Fasching B; Schuster E; Obermair A; Leodolter S; Zeillinger R
Clin Cancer Res; 2002 Jul; 8(7):2253-9. PubMed ID: 12114428
[TBL] [Abstract][Full Text] [Related]
37. Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
Maeda H; Arai Y; Ishitoya S; Okubo K; Aoki Y; Okada T; Maekawa S
Hinyokika Kiyo; 1998 May; 44(5):307-11. PubMed ID: 9656100
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
Brassell SA; Kao TC; Sun L; Moul JW
Urology; 2005 Dec; 66(6):1229-33. PubMed ID: 16360448
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen (PSA) in women.
Yu H; Berkel H
J La State Med Soc; 1999 Apr; 151(4):209-13. PubMed ID: 10234897
[TBL] [Abstract][Full Text] [Related]
40. [Prostate-specific antigen (PSA) in women].
Kamenov Z; Todorova M; Khristov V
Vutr Boles; 2001; 33(1):40-7. PubMed ID: 11785088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
